7.12
price up icon2.45%   0.17
after-market 시간 외 거래: 7.12
loading
전일 마감가:
$6.95
열려 있는:
$7
하루 거래량:
875.96K
Relative Volume:
0.89
시가총액:
$980.57M
수익:
$62.04M
순이익/손실:
$-533.34M
주가수익비율:
-1.5857
EPS:
-4.49
순현금흐름:
$-473.07M
1주 성능:
-11.11%
1개월 성능:
-6.44%
6개월 성능:
-37.38%
1년 성능:
-27.64%
1일 변동 폭
Value
$6.88
$7.27
1주일 범위
Value
$6.56
$8.02
52주 변동 폭
Value
$6.56
$13.09

비르 바이오테크 Stock (VIR) Company Profile

Name
명칭
Vir Biotechnology Inc
Name
전화
415-906-4324
Name
주소
1800 OWENS STREET, SAN FRANCISCO, CA
Name
직원
587
Name
트위터
@Vir_Biotech
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
VIR's Discussions on Twitter

VIR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
VIR 7.12 980.57M 62.04M -533.34M -473.07M -4.49
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

비르 바이오테크 Stock (VIR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-01-29 다운그레이드 JP Morgan Overweight → Neutral
2023-09-08 다운그레이드 BofA Securities Buy → Neutral
2023-03-06 업그레이드 JP Morgan Neutral → Overweight
2023-02-21 업그레이드 Goldman Neutral → Buy
2023-01-27 업그레이드 Morgan Stanley Underweight → Equal-Weight
2022-09-14 개시 SVB Leerink Outperform
2022-09-09 개시 Morgan Stanley Underweight
2022-03-03 업그레이드 Robert W. Baird Underperform → Neutral
2021-12-21 다운그레이드 Robert W. Baird Neutral → Underperform
2021-10-25 업그레이드 JP Morgan Underweight → Neutral
2021-09-22 다운그레이드 Goldman Buy → Neutral
2021-06-04 재개 Robert W. Baird Neutral
2021-01-27 다운그레이드 JP Morgan Neutral → Underweight
2021-01-20 재확인 H.C. Wainwright Buy
2020-10-05 개시 BofA Securities Buy
2020-09-14 업그레이드 Goldman Neutral → Buy
2020-09-11 업그레이드 JP Morgan Underweight → Neutral
2020-08-20 개시 Needham Buy
2020-03-19 다운그레이드 JP Morgan Neutral → Underweight
2020-03-13 다운그레이드 Goldman Buy → Neutral
2020-02-27 다운그레이드 Robert W. Baird Neutral → Underperform
2020-02-04 다운그레이드 JP Morgan Overweight → Neutral
2019-11-14 개시 Robert W. Baird Neutral
2019-11-05 개시 Barclays Overweight
2019-11-05 개시 Cowen Outperform
2019-11-05 개시 Goldman Buy
2019-11-05 개시 JP Morgan Overweight
모두보기

비르 바이오테크 주식(VIR)의 최신 뉴스

pulisher
Nov 22, 2024

Leerink Partnrs Has Bearish Outlook for VIR FY2026 Earnings - MarketBeat

Nov 22, 2024
pulisher
Nov 22, 2024

What is HC Wainwright's Estimate for VIR FY2024 Earnings? - MarketBeat

Nov 22, 2024
pulisher
Nov 20, 2024

Needham & Company LLC Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Empowered Funds LLC Sells 163,723 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat

Nov 20, 2024
pulisher
Nov 19, 2024

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace

Nov 19, 2024
pulisher
Nov 19, 2024

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace

Nov 19, 2024
pulisher
Nov 18, 2024

VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada

Nov 18, 2024
pulisher
Nov 18, 2024

Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com

Nov 18, 2024
pulisher
Nov 18, 2024

Vir Biotechnology Secures Key EU Orphan Drug Status for Hepatitis Delta Treatment | VIR Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Vir Biotechnology stock hits 52-week low at $7.08 By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 18, 2024

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com

Nov 18, 2024
pulisher
Nov 16, 2024

Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

(VIR) Proactive Strategies - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 15, 2024

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations - StreetInsider.com

Nov 15, 2024
pulisher
Nov 15, 2024

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire

Nov 15, 2024
pulisher
Nov 13, 2024

Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat

Nov 13, 2024
pulisher
Nov 08, 2024

Vir Biotechnology's EVP sells shares worth $44,453 - Investing.com India

Nov 08, 2024
pulisher
Nov 07, 2024

Vir Biotechnology's EVP sells shares worth $44,453 By Investing.com - Investing.com UK

Nov 07, 2024
pulisher
Nov 06, 2024

Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares - Investing.com India

Nov 06, 2024
pulisher
Nov 06, 2024

Leerink Partnrs Has Negative Outlook of VIR FY2024 Earnings - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

HC Wainwright Expects Lower Earnings for Vir Biotechnology - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript - MSN

Nov 06, 2024
pulisher
Nov 05, 2024

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off (NASDAQ:VIR) - Seeking Alpha

Nov 05, 2024
pulisher
Nov 05, 2024

VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com Nigeria

Nov 05, 2024
pulisher
Nov 05, 2024

Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

Trading (VIR) With Integrated Risk Controls - Stock Traders Daily

Nov 05, 2024
pulisher
Nov 04, 2024

HC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Vir Biotechnology (NASDAQ:VIR) Price Target Cut to $26.00 by Analysts at Barclays - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St

Nov 04, 2024
pulisher
Nov 04, 2024

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Finance

Nov 04, 2024
pulisher
Nov 02, 2024

Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 02, 2024
pulisher
Nov 02, 2024

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Misses Estimates By $0.51 EPS - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology Q3 2024 Earnings Preview - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Stock Traders Buy High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology (NASDAQ:VIR) Shares Gap Down on Disappointing Earnings - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Vir Biotechnology Reports Q3 2024 Financial Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - BioSpace

Oct 31, 2024
pulisher
Oct 31, 2024

Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 51c - StreetInsider.com

Oct 31, 2024

비르 바이오테크 (VIR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):